Los Angeles Capital Management LLC Raises Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Los Angeles Capital Management LLC increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 103,284 shares of the biopharmaceutical company’s stock after buying an additional 1,987 shares during the period. Los Angeles Capital Management LLC’s holdings in Halozyme Therapeutics were worth $3,817,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Advisors Asset Management Inc. increased its position in shares of Halozyme Therapeutics by 0.6% during the third quarter. Advisors Asset Management Inc. now owns 45,598 shares of the biopharmaceutical company’s stock worth $1,742,000 after acquiring an additional 287 shares during the period. First Horizon Advisors Inc. increased its holdings in Halozyme Therapeutics by 24.5% during the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 293 shares during the period. Fifth Third Bancorp raised its position in Halozyme Therapeutics by 2.6% during the 3rd quarter. Fifth Third Bancorp now owns 12,262 shares of the biopharmaceutical company’s stock valued at $468,000 after purchasing an additional 308 shares in the last quarter. Commonwealth Equity Services LLC lifted its holdings in shares of Halozyme Therapeutics by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 16,216 shares of the biopharmaceutical company’s stock worth $619,000 after buying an additional 347 shares during the period. Finally, Truist Financial Corp lifted its holdings in shares of Halozyme Therapeutics by 0.6% in the 4th quarter. Truist Financial Corp now owns 102,622 shares of the biopharmaceutical company’s stock worth $3,793,000 after buying an additional 563 shares during the period. Institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on HALO. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, April 30th. JMP Securities reaffirmed a “market outperform” rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, February 21st. TheStreet lowered shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. TD Cowen assumed coverage on shares of Halozyme Therapeutics in a research note on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price objective for the company. Finally, Benchmark reaffirmed a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday, April 16th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $53.29.

Halozyme Therapeutics Trading Up 0.2 %

Shares of NASDAQ:HALO opened at $39.91 on Monday. Halozyme Therapeutics, Inc. has a 1 year low of $29.85 and a 1 year high of $45.00. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50. The firm has a market capitalization of $5.07 billion, a P/E ratio of 18.91, a P/E/G ratio of 0.47 and a beta of 1.26. The business’s 50-day moving average is $39.99 and its 200 day moving average is $37.91.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The company had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. On average, research analysts predict that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current fiscal year.

Insider Activity

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the sale, the senior vice president now owns 156,558 shares in the company, valued at approximately $6,519,075.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 30,000 shares of company stock valued at $1,196,800 over the last ninety days. 2.70% of the stock is currently owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.